NGM Biopharmaceuticals Inc

NGMDelisted Apr 5, 2024

Industry: Pharmaceutical Preparations
SEC CIK: 0001426332

SEC filings (opens in a new tab)

NGM Biopharmaceuticals Inc was delisted on Apr 5, 2024; its insiders filed their last Form 4 on Apr 8, 2024; 75 institutions reported holding it in 13F filings for Q1 2024, worth $55.1M in total; no superinvestor held it.

Q3 2022 vs. Q2 2022

How the institutions holding NGM Biopharmaceuticals Inc changed between Q2 2022 and Q3 2022.

All holders in Q3 2022 All holders in Q2 2022

13F holders of NGM: Q2 2022 compared with Q3 2022
Measure	Q2 2022	Of which not filed for Q3 2022	Q3 2022	Change
Holders	124	1	128	+5
Shares	47.3M	12	52.8M	+5.42M (+11.4%)
Value	$607.3M	$154	$689.9M	+$82.6M (+13.6%)

1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (22)

Institutions that held NGM Biopharmaceuticals Inc at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to NGM in Q3 2022
Institution	Shares	Value	% of portfolio
Avidity Partners Management LP	1,798,100	$23.5M	0.51%
Logos Global Management LP	850,000	$11.1M	1.37%
Great Point Partners LLC	316,256	$4.14M	1.00%
Pura Vida Investments, LLC	135,696	$1.77M	0.27%
Jennison Associates LLC	122,430	$1.60M	0.00%
Schonfeld Strategic Advisors LLC	72,382	$946.0K	0.01%
Jacobs Levy Equity Management, Inc	68,649	$898.0K	0.01%
Caption Management, LLC	61,970	$810.0K	0.14%
ExodusPoint Capital Management, LP	52,672	$689.0K	0.01%
Parkwood LLC	44,314	$580.0K	0.12%
Trexquant Investment LP	35,245	$461.0K	0.02%
PDT Partners, LLC	34,267	$448.0K	0.07%
Squarepoint Ops LLC	25,914	$339.0K	0.00%
Walleye Capital LLC	14,669	$192.0K	0.00%
Los Angeles Capital Management LLC	11,919	$156.0K	0.00%
Gsa Capital Partners LLP	11,059	$145.0K	0.02%
Acuta Capital Partners, LLC	7,500	$98.0K	0.04%
Group One Trading, L.P.	4,290	$56.0K	0.00%
China Universal Asset Management Co., Ltd.	752	$10.0K	0.00%
Massmutual Trust Co FSB	137	$2.00K	0.00%
CWM, LLC	184	$2.00K	0.00%
ClariVest Asset Management LLC	57	$1.00K	0.00%

Sold out (17)

Institutions that held NGM Biopharmaceuticals Inc at the end of Q2 2022 and filed for Q3 2022 without it.

Institutions that sold out of NGM in Q3 2022
Institution	Shares, Q2 2022	Value, Q2 2022
Partners Group Holding AG	177,255	$2.27M
Woodline Partners LP	134,188	$1.72M
Lexington Partners L.P.	110,428	$1.42M
Blackstone Group Inc.	104,432	$1.34M
Baker Bros. Advisors LP	55,294	$709.0K
Washington University	44,314	$568.0K
Hamilton Lane Advisors LLC	37,503	$481.0K
XTX Topco Ltd	34,571	$443.0K
Wellington Management Group LLP	27,005	$346.0K
Engineers Gate Manager LP	27,026	$346.0K
Common Fund for Nonprofit Organizations	17,725	$227.2K
Acadian Asset Management LLC	16,716	$214.0K
ETF Managers Group, LLC	15,271	$196.0K
Graham Capital Management, L.P.	12,492	$160.0K
Allspring Global Investments Holdings, LLC	569	$7.00K
Quadrant Capital Group LLC	22	$0
State of Wyoming	25	$0

Not filed for Q3 2022 yet (1)

Institutions that held NGM Biopharmaceuticals Inc at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding NGM in Q2 2022 that haven't filed for Q3 2022
Institution	Shares, Q2 2022	Value, Q2 2022
Exane Derivatives	12	$154